Loading organizations...
§ Venture Capital · Palo Alto, CA, USA
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Vivo Capital is an investment firm specializing in global healthcare and biotechnology sectors. It utilizes a multi-strategy approach, encompassing venture capital, private equity, and public equity to invest in companies. The firm targets entities developing novel treatments and technologies, primarily within biopharmaceuticals and medical devices, across development stages.
Established in 1996 by Frank Kung and Edgar G. Engleman, the firm was initially named BioAsia Investments. Their founding insight stemmed from a deep understanding of the biopharmaceutical industry, having previously co-founded Genelabs Technologies. This company's later acquisition provided them critical experience to launch their dedicated healthcare investment platform.
Vivo Capital's portfolio companies operate across the healthcare continuum, from early-stage innovations to growth-stage firms. These enterprises focus on developing diverse biotechnology and medical device solutions aimed at advancing patient care. The firm consistently seeks to identify and support ventures poised to deliver meaningful breakthroughs in global health.
Key people at Vivo Capital.
Vivo Capital is a global healthcare-focused investment firm with approximately $5.8 billion in assets under management (AUM) as of late 2024. The firm’s mission is to catalyze innovation and growth in healthcare by supporting companies that expand access to medical technologies and therapies. Vivo employs a multi-strategy investment platform, spanning venture capital, private equity, and public equity, with a focus on biotechnology, pharmaceuticals, medical devices, and life sciences. Its investment philosophy centers on an “Ecosystem Strategy,” leveraging deep networks and cross-sector collaborations to create proprietary opportunities and accelerate portfolio company growth. Vivo’s impact is evident in its support for over 430 global healthcare companies, driving innovation and commercialization across the industry value chain.
Founded in 1996 in Palo Alto, California, Vivo Capital traces its roots to the BDF Fund, established by Dr. Frank Kung and Dr. Edgar Engleman, both prominent figures in biotech and medicine. Initially focused on biotech venture investments, the firm began exploring opportunities in Asia’s healthcare market in the early 2000s, eventually establishing a presence in China and later Singapore. Over time, Vivo evolved into a multi-stage, global investment platform, launching dedicated funds for venture, private equity, and public equities. This expansion allowed Vivo to adapt to changing market dynamics and capture opportunities across the healthcare innovation lifecycle.
Vivo Capital is riding the wave of global healthcare innovation, fueled by advances in biotechnology, digital health, and personalized medicine. The firm’s timing is critical as healthcare systems worldwide face increasing pressure to deliver more effective, accessible, and affordable care. Vivo’s ecosystem-driven approach aligns with broader trends toward collaboration and integration in healthcare, enabling it to influence the sector’s evolution. By supporting startups and scaling companies, Vivo helps shape the future of medical technologies and therapies, contributing to a more resilient and innovative healthcare ecosystem.
Looking ahead, Vivo Capital is well-positioned to continue shaping the global healthcare landscape. As biotech and digital health sectors mature, the firm’s multi-strategy platform and ecosystem approach will remain key differentiators. Vivo is likely to deepen its focus on emerging markets, expand its network, and explore new investment opportunities in areas like AI-driven drug discovery and precision medicine. The firm’s influence will grow as it helps bridge gaps between innovation and commercialization, ultimately driving better health outcomes worldwide. Vivo’s journey reflects its founding mission: to catalyze innovation and expand access to healthcare, a vision that will remain central to its future success.
Key people at Vivo Capital.
Vivo Capital has more than 26 tracked investments across 24 companies. The latest tracked deal is $103.0M Series B in Kinaset Therapeutics in January 2026.
